Multimodal Therapy in the Treatment of XXXX : The Johns Hopkins Experience.

@entity1 @entity1069 @entity5 @entity3 @entity1876 @entity1349
BACKGROUND: The objective of this study was to evaluate the use of neoadjuvant chemoradiation in @entity1 with @entity1069 treated at our institution and report oncological outcomes. MATERIALS AND METHODS: The records of @entity1 with intermediate- or high-grade @entity1069 treated with curative intent at our institution from 1993 to 2013 were reviewed. @entity1 @entity5 characteristics, and treatment modalities used were assessed. Overall survival (OS), @entity5 -specific survival (CSS), and @entity1349 ( @entity1349 ) were calculated. RESULTS: Eight @entity1 met inclusion criteria. The mean age at presentation was 64 years, and @entity1876 was the most common presenting symptom. All @entity1 underwent surgical resection and neoadjuvant radiation and 6 had concurrent chemotherapy. Four @entity1 received intraoperative radiation. With a median follow-up of 36 months, there were no local recurrences, 6 @entity3 , 4 deaths from disease, and no deaths from other causes. The median OS and CSS was 67.8 months, with actuarial OS and CSS rates of 100% at 1 year, 75% at 2 years, 62.5% at 3 years, and 62.5% at 5 years. Median @entity1349 was 14.2 months, with actuarial @entity1349 rate of 75% at 1 year, 37.5% at 2 years, and 25% at 3 years. CONCLUSION: @entity1069 are rarely cured using surgical resection alone. Our cohort treated with a multimodality approach had favorable CSS and @entity1349 compared with historic and contemporary series of surgery alone and no local recurrences. Most @entity1 developed metastatic recurrence, highlighting the aggressive nature of this disease.
